Takeda Pharmaceutical Files April 2025 6-K Report
Ticker: TKPHF · Form: 6-K · Filed: Apr 22, 2025 · CIK: 1395064
| Field | Detail |
|---|---|
| Company | Takeda Pharmaceutical Co Ltd (TKPHF) |
| Form Type | 6-K |
| Filed Date | Apr 22, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: reporting, foreign-private-issuer
TL;DR
Takeda filed its April 6-K, confirming 20-F annual reports. Standard procedure.
AI Summary
Takeda Pharmaceutical Company Limited filed a Form 6-K on April 22, 2025, reporting as a foreign private issuer. The filing is for the month of April 2025 and indicates Takeda will file its annual reports under Form 20-F. The company's principal executive offices are located in Tokyo, Japan.
Why It Matters
This filing serves as an update for investors regarding Takeda's reporting status and administrative information as a foreign private issuer.
Risk Assessment
Risk Level: low — This is a routine administrative filing and does not contain new financial or operational information that would typically impact risk.
Key Players & Entities
- Takeda Pharmaceutical Company Limited (company) — Filer
- Tokyo, Japan (location) — Principal executive offices location
FAQ
What type of report is Takeda Pharmaceutical filing?
Takeda Pharmaceutical is filing a Form 6-K, which is a Report of Foreign Private Issuer.
What is the filing date of this Form 6-K?
This Form 6-K was filed on April 22, 2025.
Under which form does Takeda Pharmaceutical file its annual reports?
Takeda Pharmaceutical indicates it files its annual reports under Form 20-F.
Where are Takeda Pharmaceutical's principal executive offices located?
Takeda Pharmaceutical's principal executive offices are located at 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo 103-8668, Japan.
Is Takeda Pharmaceutical submitting this Form 6-K in paper format?
The filing does not indicate that Takeda Pharmaceutical is submitting the Form 6-K in paper format as permitted by Regulation S-T Rule 101(b)(1) or Rule 101(b)(7).
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on April 22, 2025 regarding TAKEDA PHARMACEUTICAL CO LTD (TKPHF).